Public money, private patents? Unravelling India’s opacity over its Covid vaccines
Public money, private patents: Unravelling India’s opacity over its Covid vaccines
Newslaundry ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
UNBELIEVABLE: Gennova biopharmaceuticals - The Untold Story
India-made mRNA vaccine priced at ₹2,292, will be available as a booster dose
India’s first indigenously developed mRNA vaccine against the dominant Omicron variant of the COVID-19 coronavirus will cost ₹2,292, Sanjay Singh, CEO, Gennova Biopharmaceuticals, said at a press conference on June 24.
The Hindu ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Newslaundry
The Hindu
People
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Organisations
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Topics
Places
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
